Patients with DM can suffer compromised synovium function, as the development of synovial insulin resistance under hyperglycemic conditions reduces the ability of insulin to regulate glucose levels and suppress the production of inflammatory mediators known to stimulate the progression of OA (King and Rosenthal, 2015; Griffin and Huffman, 2016). The gene discussed is INS; the disease is Insulin resistance.